Although there are over 400 ETFs on the ASX, the best performing ASX ETFs stand head and shoulders above their peers. This article outlines the top 6 and why each has done so well.
What are the Best ASX Stocks to invest in right now?
Check our buy/sell tips
[sg_popup id="23914" event="click"][/sg_popup]
6 of the Best Performing ASX…
Prescient Therapeutics' (ASX:PTX) trial of PTX-100 against T-Cell Lymphoma is well and truly underway now with 8 out of 16 trial sites set up. This significant milestone provides significant hope to sufferers of this disease as well as to the company's investors.
What are the Best ASX Biotech Stocks to invest in right now?
Check our…
Amcor (ASX:AMC) is celebrating its 100th anniversary later this year, but it would seem there's little else to celebrate right now. Perhaps the dividend yield, but of course the high yield is more because of the lower share price than because of the higher dividend.
It is true that few names on the ASX carry the…
It is easy to think of ASX Stocks that are a compelling case to buy, but tougher to think of ASX Stocks Not To Buy. Often, people are lured into companies because they represent compelling thematic right now: surging gold prices, copper's electrification boom, resilient healthcare demand, and a quick-service restaurant sector that keeps growing.
But not…
There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at.
For those who don't know what the patent cliff is, it is is one of the most consequential forces in global pharmaceuticals. The concept of a big pharma's drug losing exclusivity and having…
Ross Stores (NDQ:ROST) is an S&P 500 company that is well and truly for the working class, being America's largest discount apparel retailer.
Even though the US economy is going strong and inflation is coming under control, this is not necessarily being felt across the country. This has been reflected in the company's sales (surpassing US$20bn…
Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?
After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear, and arguably feared more and more as the week with trading suspended went on. Namely, its most advanced clinical trial for Efti is all over red rover!
While it is not the end of the company,…
In a couple of weeks, some ASX Stocks Are Being Removed from the ASX All Ords. Other companies will take their place and it was only yesterday that we wrote about that fact and some of the companies being promoted. But today it is time to look at the stocks suffering the indignity of being…
GemLife Communities (ASX:GLF) only listed in the middle of last year but has made its mark on the ASX, gaining over 20% since its debut and joining the ASX All Ords in the next index rebalance.
There's something peculiar about this $1.9bn company, in our view. Namely, that it could be a way to play the…
Twice a year, specifically on the third Fridays of March and September, the list of ASX All Ordinaries Stocks changes as stocks are added and demoted. Their promotions and demotions happen for various reasons that all feed into an increase or decrease in the company's market capitalisation.
In this article, we look at 8 companies that…
